Hormone Therapy Extends Lives of Ovarian Cancer Patients

Related Encyclopedia • Adenocarcinoma of the Lung and Brain Metastases • Amenorrhea • Amniocentesis • Amniocentesis and CVS More... Related Healthscout Videos Zapping Vocal Tumors Keep Away Ovarian Cancer Breakthrough for Fatal Lung Disease Preventing Breast Cancer More... Related Animations • Breast Reduction • Breast Self-Exam Video • Colon Cancer • Erectile Dysfunction More... Related Drug Information • Actonel • Detrol LA • Diflucan • Ditropan XL More... Related News Articles • Method for Treating Cervical Lesions May Pose Pregnancy Risks • Stretching Exercises May Protect Against Preeclampsia • Nervous System Controls Weight • Preventing PTSD More...

Page:  << Prev | 1 | 2

The American Cancer Society reports that ovarian cancer is the eighth most common cancer in women, not including skin cancer. There will be about 22,430 new cases of ovarian cancer in the United States this year, and an estimated 15,280 women will die from the disease.

A large majority -- about two-thirds -- of women with ovarian cancer are 55 or older. A woman's risk of getting ovarian cancer is about one in 67, according to the cancer society.

Dr. Len Lichtenfeld, the deputy chief medical officer at the American Cancer Society, said, "Letrozole is already approved for treating ovarian cancer in women who have failed other treatment. This study refines these researchers' previous work by identifying those women with estrogen-receptor-sensitive ovarian cancer who are the most likely to respond to this drug.

Text Continues Below

---

"Whether the drug should be started earlier in the course of ovarian cancer and whether we should be evaluating whether or not a woman has estrogen-receptor-sensitive ovarian cancer are questions that need to be answered," he said.

More information

For more information on ovarian cancer, visit the American Cancer Society.

Page:  << Prev | 1 | 2